WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009139004) TAT DNA SEQUENCES, GENE CONSTRUCTS, VACCINE AND PROCESSES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/139004    International Application No.:    PCT/IN2009/000284
Publication Date: 19.11.2009 International Filing Date: 14.05.2009
Chapter 2 Demand Filed:    25.01.2010    
IPC:
C12N 15/48 (2006.01), A61K 31/7088 (2006.01), A61P 31/18 (2006.01)
Applicants: JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH [IN/IN]; Deemed University Jakkur, Bangalore, Karnataka 560 064 (IN) (For All Designated States Except US).
RANGA, Udaykumar [IN/IN]; (IN) (For US Only)
Inventors: RANGA, Udaykumar; (IN)
Agent: BHOLA, Ravi; K&S Partners #4121/B, 6th Cross 19A Main HAL II Stage [Extension] Bangalore, Karnataka 560 038 (IN)
Priority Data:
01174/CHE/2008 14.05.2008 IN
Title (EN) TAT DNA SEQUENCES, GENE CONSTRUCTS, VACCINE AND PROCESSES THEREOF
(FR) SÉQUENCES D’ADN TAT, GÈNES CHIMÈRES, VACCIN ET PROCÉDÉS ASSOCIÉS
Abstract: front page image
(EN)The present invention relates to non toxic, immunogenic viral Tat DNA sequences comprising wherein the Tat Sequence is rendered non toxic and immunogenic by insertion of T-Helper Epitope into the Cysteine-rich domain, or Basic domain or Core domain of said Tat DNA sequence, optionally along with insertion of a synthetic Intron between C-terminal region and Exon II region of the Tat DNA Sequence. The present invention also relates to elongation factor promoter constructs and process thereof. Also the present invention relates to a process of obtaining the non toxic and immunogenic Tat DNA sequence and vaccine and a method thereof.
(FR)La présente invention concerne des séquences d’ADN Tat virales immunogènes et non toxiques, dans lesquelles la séquence Tat est rendue non toxique et immunogène par insertion d’un épitope T auxiliaire dans le domaine riche en cystéine, ou dans le domaine basique ou le domaine central de ladite séquence d’ADN Tat, facultativement associée à l’insertion d’un intron synthétique entre la région C-terminale et la région Exon II de la séquence d’ADN Tat. La présente invention concerne également  des gènes chimères promoteurs de facteur d’allongement et les procédés associés. La présente invention concerne également un procédé permettant d’obtenir la séquence d’ADN Tat non toxique et immunogène et un vaccin et un procédé associé.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)